Silver Book Fact

Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of close to $4 trillion per year.

Vernon J, Goldberg R, Dash Y, Muralimohan G. Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?. Working Paper — Pending Publication; 2007. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12477

Reference

Title
Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?
Publisher
Working Paper — Pending Publication
Publication Date
2007
Authors
Vernon J, Goldberg R, Dash Y, Muralimohan G
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.  
  • In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.  
  • A treatment breakthrough that slowed the progression of Alzheimer’s disease would reduce the number of people with the disease from 2.4 million to 1.1 million in 2020, and from 6.5…  
  • Out-of-Pocket Costs, 5-Year Delayed Onset  
  • An Alzheimer’s disease treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce Medicaid costs for people with the disease by $14 billion in 2020–from…